Localization and expression of substance P in transgenic mice overexpressing human APP751 with the London (V717I) and Swedish (K670M/N671L) mutations

Brain Research

Volumn 1143, Issue 1, 2007, Pages 199-207

  Willis, Michael ^a   Hutter Paier, Birgit ^b   Wietzorrek, Georg ^a   Windisch, Manfred ^b   Humpel, Christian ^a   Knaus, Hans Günther ^a   Marksteiner, Josef ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b JSW Life Sciences GmbH   (Austria)

Author keywords

Alzheimer; Amyloid; APP; Astrocyte; GFAP; Substance P; Transgenic animal

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AMYLOID PRECURSOR PROTEIN 751; GLIAL FIBRILLARY ACIDIC PROTEIN; SUBSTANCE P; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; GENE EXPRESSION; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOUSE; NEURITE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; THALAMUS; TRANSGENIC MOUSE;

AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ASPARTIC ACID; GENE EXPRESSION; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; ISOLEUCINE; LEUCINE; LYSINE; METHIONINE; MICE; MICE, TRANSGENIC; MUTATION; SUBSTANCE P; VALINE;

ANIMALIA; MUS MUSCULUS;

EID: 33947323772     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.01.080     Document Type: Article

References (48)

1. Ahmed M.M., Hoshino H., Chikuma T., Yamada M., and Kato T. Effect of memantine on the levels of glial cells, neuropeptides, and peptide-degrading enzymes in rat brain regions of ibotenic acid-treated Alzheimer's disease model. Neuroscience 126 (2004) 639-649
2. Annunziata P., Cioni C., Santonini R., and Paccagnini E. Substance P antagonist blocks leakage and reduces activation of cytokine-stimulated rat brain endothelium. J. Neuroimmunol. 131 (2002) 41-49
3. Armstrong D.M., Benzing W.C., Evans J., Terry R.D., Shields D., and Hansen L.A. Substance P and somatostatin coexist within neuritic plaques: implications for the pathogenesis of Alzheimer's disease. Neuroscience 31 (1989) 663-671
4. Beal M.F., and Mazurek M.F. Substance P-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. Neurology 37 (1987) 1205-1209
5. Beresford I.J., Birch P.J., Hagan R.M., and Ireland S.J. Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345. Br. J. Pharmacol. 104 (1991) 292-293
6. Diez M., Koistinaho J., Kahn K., Games D., and Hokfelt T. Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F beta-amyloid precursor protein-initial observations. Neuroscience 100 (2000) 259-286
7. Eikelenboom P., Bate C., van Gool W.A., Hoozemans J.J., Rozemuller J.M., Veerhuis R., and Williams A. Neuroinflammation in Alzheimer's disease and prion disease. Glia 40 (2002) 232-239
8. El Agnaf O.M., Irvine G.B., Fitzpatrick G., Glass W.K., and Guthrie D.J. Comparative studies on peptides representing the so-called tachykinin-like region of the Alzheimer Abeta peptide [Abeta(25-35)]. Biochem. J. 336 Pt. 2 (1998) 419-427
9. Forloni G., Mangiarotti F., Angeretti N., Lucca E., and De Simoni M.G. Beta-amyloid fragment potentiates IL-6 and TNF-alpha secretion by LPS in astrocytes but not in microglia. Cytokine 9 (1997) 759-762
10. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., and Gillespie F. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373 (1995) 523-527
11. Grace E.A., Rabiner C.A., and Busciglio J. Characterization of neuronal dystrophy induced by fibrillar amyloid beta: implications for Alzheimer's disease. Neuroscience 114 (2002) 265-273
12. Hasenohrl R.U., Souza-Silva M.A., Nikolaus S., Tomaz C., Brandao M.L., Schwarting R.K., and Huston J.P. Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. Neuropeptides 34 (2000) 272-280
13. Hokfelt T., and Kuteeva E. Substance P: a neuropeptide. Am. J. Psychiatry 163 (2006) 578
14. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., Kholodenko D., Malenka R.C., Nicoll R.A., and Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3228-3233
15. Hull M., Muksch B., Akundi R.S., Waschbisch A., Hoozemans J.J., Veerhuis R., and Fiebich B.L. Amyloid beta peptide (25-35) activates protein kinase C leading to cyclooxygenase-2 induction and prostaglandin E(2) release in primary midbrain astrocytes. Neurochem. Int. 48 8 (2006) 663-672
16. Kart E., Jocham G., Muller C.P., Schlomer C., Brandao M.L., Huston J.P., and Souza Silva M.A. Neurokinin-1 receptor antagonism by SR140333: enhanced in vivo ACh in the hippocampus and promnestic post-trial effects. Peptides 25 (2004) 1959-1969
17. Kavelaars A., Broeke D., Jeurissen F., Kardux J., Meijer A., Franklin R., Gelfand E.W., and Heijnen C.J. Activation of human monocytes via a non-neurokinin substance P receptor that is coupled to Gi protein, calcium, phospholipase D, MAP kinase, and IL-6 production. J. Immunol. 153 (1994) 3691-3699
18. King M.E., Kan H.M., Baas P.W., Erisir A., Glabe C.G., and Bloom G.S. Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J. Cell Biol. 175 (2006) 541-546
19. Kostyk S.K., Kowall N.W., and Hauser S.L. Substance P immunoreactive astrocytes are present in multiple sclerosis plaques. Brain Res. 504 (1989) 284-288
20. Kowall N.W., Quigley Jr. B.J., Krause J.E., Lu F., Kosofsky B.E., and Ferrante R.J. Substance P and substance P receptor histochemistry in human neurodegenerative diseases. Regul. Pept. 46 (1993) 174-185
21. Langosch J.M., Kupferschmid S., Heinen M., Walden J., Herpfer I., Fiebich B.L., and Lieb K. Effects of substance P and its antagonist L-733060 on long term potentiation in guinea pig hippocampal slices. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 29 (2005) 315-319
22. Lieb K., Fiebich B.L., Berger M., Bauer J., and Schulze-Osthoff K. The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J. Immunol. 159 (1997) 4952-4958
23. Lin R.C. Reactive astrocytes express substance-P immunoreactivity in the adult forebrain after injury. NeuroReport 7 (1995) 310-312
24. Luber-Narod J., Kage R., and Leeman S.E. Substance P enhances the secretion of tumor necrosis factor-alpha from neuroglial cells stimulated with lipopolysaccharide. J. Immunol. 152 (1994) 819-824
25. Mantyh P.W. Neurobiology of substance P and the NK1 receptor. J. Clin. Psychiatry 63 Suppl. 11 (2002) 6-10
26. Marksteiner J., Saria A., and Krause J.E. Comparative distribution of neurokinin B-, substance P- and enkephalin-like immunoreactivities and neurokinin B messenger RNA in the basal forebrain of the rat: evidence for neurochemical compartmentation. Neuroscience 51 (1992) 107-120
27. Marksteiner J., Sperk G., and Krause J.E. Distribution of neurons expressing neurokinin B in the rat brain: immunohistochemistry and in situ hybridization. J. Comp. Neurol. 317 (1992) 341-356
28. Marriott I. The role of tachykinins in central nervous system inflammatory responses. Front. Biosci. 9 (2004) 2153-2165
29. Meda L., Cassatella M.A., Szendrei G.I., Otvos Jr. L., Baron P., Villalba M., Ferrari D., and Rossi F. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 374 (1995) 647-650
30. Meda L., Baron P., and Scarlato G. Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins. Neurobiol. Aging 22 (2001) 885-893
31. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., and McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20 (2000) 4050-4058
32. Nag S., and Tang F. Cholinergic lesions of the rat brain by ibotenic acid and 192 IgG-saporin: effects on somatostatin, substance P and neuropeptide Y levels in the cerebral cortex and the hippocampus. Neurosci. Lett. 252 (1998) 83-86
33. Palma C., Minghetti L., Astolfi M., Ambrosini E., Silberstein F.C., Manzini S., Levi G., and Aloisi F. Functional characterization of substance P receptors on cultured human spinal cord astrocytes: synergism of substance P with cytokines in inducing interleukin-6 and prostaglandin E2 production. Glia 21 (1997) 183-193
34. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., and Cotman C.W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13 (1993) 1676-1687
35. Quigley Jr. B.J., and Kowall N.W. Substance P-like immunoreactive neurons are depleted in Alzheimer's disease cerebral cortex. Neuroscience 41 (1991) 41-60
36. Reinke E., and Fabry Z. Breaking or making immunological privilege in the central nervous system: the regulation of immunity by neuropeptides. Immunol. Lett. (2005)
37. Rigby M., O'Donnell R., and Rupniak N.M. Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain. J. Comp. Neurol. 490 (2005) 335-353
38. Rockenstein E., Mallory M., Mante M., Sisk A., and Masliaha E. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J. Neurosci. Res. 66 (2001) 573-582
39. Selkoe D.J. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 275 (1997) 630-631
40. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 298 (2002) 789-791
41. Souza Silva M.A., Hasenohrl R.U., Tomaz C., Schwarting R.K., and Huston J.P. Differential modulation of frontal cortex acetylcholine by injection of substance P into the nucleus basalis magnocellularis region in the freely-moving vs. the anesthetized preparation. Synapse 38 (2000) 243-253
42. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., and Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 13287-13292
43. Tomidokoro Y., Harigaya Y., Matsubara E., Ikeda M., Kawarabayashi T., Okamoto K., and Shoji M. Impaired neurotransmitter systems by Abeta amyloidosis in APPsw transgenic mice overexpressing amyloid beta protein precursor. Neurosci. Lett. 292 (2000) 155-158
44. Van Eldik L.J. Glia and Alzheimer's disease. Neurochem. Int. 39 (2001) 329-331
45. Vishwanath R., and Mukherjee R. Substance P promotes lymphocyte-endothelial cell adhesion preferentially via LFA-1/ICAM-1 interactions. J. Neuroimmunol. 71 (1996) 163-171
46. Yankner B.A., Duffy L.K., and Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250 (1990) 279-282
47. Yew D.T., Li W.P., Webb S.E., Lai H.W., and Zhang L. Neurotransmitters, peptides, and neural cell adhesion molecules in the cortices of normal elderly humans and Alzheimer patients: a comparison. Exp. Gerontol. 34 (1999) 117-133
48. Zhang L., Zhao W., Li B., Alkon D.L., Barker J.L., Chang Y.H., Wu M., and Rubinow D.R. TNF-alpha induced over-expression of GFAP is associated with MAPKs. NeuroReport 11 (2000) 409-412